Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [ 3H]noradrenaline and [ 3H]5-HT transport in mammalian cell lines

British Journal of Pharmacology

Volumn 152, Issue 7, 2007, Pages 1121-1130

  Montgomery, T ^a   Buon, C ^a   Eibauer, S ^a   Guiry, P J ^a   Keenan, A K ^a   McBean, G J ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

5 hydroxytryptamine; HEK cells; MDMA; Noradrenaline; PC12 cells; Transport

Indexed keywords

2,3 METHYLENEDIOXYMETHAMPHETAMINE; 2,5 DIMETHOXY 4 BROMOPHENYLETHYLAMINE; 3 O METHYL ALPHA METHYLDOPAMINE; 3,4 DIMETHOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE DERIVATIVE; 3,4 METHYLENEDIOXYPHENYL 2 BUTANAMINE; 3,4 METHYLENEDIOXYPHENYL N METHYL 2 BUTANAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; N HYDROXY 3,4 METHYLENEDIOXYAMPHETAMINE; NORADRENALIN TRANSPORTER; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE; PC12 CELLS; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 36448933846     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707473     Document Type: Article

References (58)

1. Anderson WK, Dabrah TT, Houston MD (1987). Synthesis of erbstatin, a naturally occurring inhibitor of tyrosine-specific protein kinase. J Org Chem 52: 1945-1947.
2. Becker J, Neis P, Rohrich J, Zorntlein S (2003). A fatal paramethoxymethamphetamine intoxication. Leg Med (Tokyo) 5 (Suppl 1): S138-S141.
3. Braun U, Shulgin AT, Braun G (1980). Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4- methylenedioxyamphetamine). J Pharm Sci 69: 192-195.
4. Breier JM, Bankson MG, Yamamoto BK (2006). L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions. J Neurosci 26: 290-299.
5. Bronson ME, Jiang W, DeRuiter J, Clark CR (1995). Structure-activity relationships of BDB and its monomethyl and dimethyl derivatives. Pharmacol Biochem Behav 51: 477-479.
6. Cheng JY, Chan MF, Chan TW, Hung MY (2006). Impurity profiling of ecstasy tablets seized in Hong Kong by gas chromatography-mass spectrometry. Forensic Sci Int 162: 87-94.
7. Colado MI, O'Shea E, Green AR (2004). Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) 173: 249-263.
8. de Boer D, Gijzels MJ, Bosman IJ, Maes RAA (1999). More data about the new psychoactive drug 2C-B. J Anal Toxicol 23: 227-228.
9. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M et al. (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26: 137-144.
10. Escobedo I, O'Shea E, Orio L, Sanchez V, Segura M, de la Torre R et al. (2005). A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br J Pharmacol 144: 231-241.
11. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT et al. (2002). The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135: 649-656.
12. Freudenmann RW, Spitzer M (2004). The neuropsychopharmacology and toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Rev 10: 89-116.
13. Fuller RW, Snoddy HD, Molloy BB (1975). Blockade of amine depletion by nisoxetine in comparison to other uptake inhibitors. Psychopharmacol Commun 1: 455-464.
14. Furnari C, Ottaviano V, Rosati F, Tondi V (1998). Identification of 3,4-methylenedioxyamphetamine analogs encountered in clandestine tablets. Forensic Sci Int 92: 49-58.
15. Giroud C, Augsburger M, Rivier L, Mangin P, Sadeghipour F, Varesio E et al. (1998). 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market. J Anal Toxicol 22: 345-354.
16. Glennon RA, Misenheimer BR (1989). Stimulus effects of N-monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from saline. Pharmacol Biochem Behav 33: 909-912.
17. Glennon RA, Titeler M, Lyon RA (1988). A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol Biochem Behav 30: 597-601.
18. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463-508.
19. Greene LA, Tischler AS (1976). Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73: 2424-2428.
20. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, de la Torre R et al. (2005). Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313: 422-431.
21. Kintz P (1997). Excretion of MBDB and BDB in urine, saliva, and sweat following single oral administration. J Anal Toxicol 21: 570-575.
22. Kintz P, Samyn N (1999). Determination of 'Ecstasy' components in alternative biological specimens. J Chromatogr B Biomed Sci Appl 733: 137-143.
23. Kronstrand R (1996). Identification of N-methyl-1-(3,4- methylenedioxyphenyl)-2-butanamine (MBDB) in urine from drug users. J Anal Toxicol 20: 512-516.
24. Lemberger L, Terman S, Rowe H, Billings R (1976). The effect of nisoxetine (Lilly compound 94939), a potential antidepressant on biogenic amine uptake in man. Br J Clin Pharmacol 3: 215-220.
25. Lyvers M (2006). Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issues. Drug Alcohol Rev 25: 269-276.
26. Milhazes N, Cunha-Oliveira T, Martins P, Garrido J, Oliveira C, Cristina Rego A et al. (2006). Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ('ecstasy') and its metabolites on undifferentiated PC12 Cells: a putative structure-toxicity relationship. Chem Res Toxicol 19: 1294-1304.
27. Monks TJ, Jones DC, Bai F, Lau SS (2004). The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 26: 132-136.
28. Morton J (2005). Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 5: 79-86.
29. Munehiro K, Hitoshi T (2002). Update on clandestine amphetamines and their analogues recently seen in Japan. J Health Sci 48: 14-21.
30. Nagai F, Nonaka R, Satoh K, Kamimura H (2007). The effects of nonmedically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559: 132-137.
31. Nagai T, Matsushima K, Suzuki A, Saotome A, Kurosu A, Nihei H et al. (2002). Enantiomer analysis of a new street drug, 3,4-methylenedioxy- N-methyl-butanamine, in rat urine. J Anal Toxicol 26: 104-109.
32. Nichols DE, Hoffman AJ, Oberlender RA, Jacob III P, Shulgin AT (1986). Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem 29: 2009-2015.
33. Oberlender R, Nichols DE (1988). Drug discrimination studies with MDMA and amphetamine. Psychopharmacology (Berl) 95: 71-76.
34. Oberlender R, Nichols DE (1990). N-methyl-1-(1,3-benzodioxol-5-yl)-2- butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy- methamphetamine-like behavioral activity. J Pharmacol Exp Ther 255: 1098-1106.
35. Pifl C, Agneter E, Drobny H, Sitte HH, Singer EA (1999). Amphetamine reverses or blocks the operation of the human noradrenaline transporter depending on its concentration: superfusion studies on transfected cells. Neuropharmacology 38: 157-165.
36. Pifl C, Nagy G, Berenyi S, Kattinger A, Reither H, Antus S (2005). Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters. J Pharmacol Exp Ther 314: 346-354.
37. Refstad S (2003). Paramethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects. Acta Anaesthesiol Scand 47: 1298-1299.
38. Rothman RB, Baumann MH (2003). Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479: 23-40.
39. Rothman RB, Baumann MH (2006). Balance between dopamine and serotonin release modulates behavioural effects of amphetamine-type drugs. Ann NY Acad Sci 1074: 245-260.
40. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI et al. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
41. Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH (2006). Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). J Psychopharmacol 20: 456-463.
42. Shulgin AT (1978). Psychotomimetic drugs: structure-activity relationships. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of Psychopharmacology. Plenum: New York, pp 243-333.
43. Shulgin AT, Carter MF (1975). Centrally active phenethylamines. Psychopharmacol Commun 1: 93-98.
44. Siedel S, Singer EA, Just H, Farhan H, Scholze P, Kudlacek O et al. (2005). Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores amphetamine action. Mol Pharmacol 67: 140-151.
45. Simonsen KW, Kaa E (2001). Designer drugs in Jutland. Ugeskr Laeger 163: 2248-2252.
46. 3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36: 2297-2303.
47. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75: 406-433.
48. Tanner-Smith EE (2006). Pharmacological content of tablets sold as 'ecstasy': results from an online testing service. Drug Alcohol Depend 83: 247-254.
49. Tate CG, Haase J, Baker C, Boorsma M, Magnani F, Vallis Y et al. (2003). Comparison of seven different heterologous protein expression systems for the production of the serotonin transporter. Biochim Biophys Acta 1610: 141-153.
50. Teng SF, Wu SC, Liu C, Li JH, Chien CS (2006). Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. Forensic Sci Int 161: 202-208.
51. Thomas DR, Nelson DR, Johnson AM (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 93: 193-200.
52. Titeler M, Lyon RA, Glennon RA (1988). Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl) 94: 213-216.
53. UNODC (2006). World drug report. Vol. 1, United Nations publications: New York.
54. Vaiva G, Bailly D, Boss V, Thomas P, Lestavel P, Goudemand M (2001a). A case of acute psychotic episode after a single dose of ecstasy. Encephale 27: 198-202.
55. Vaiva G, Boss V, Bailly D, Thomas P, Lestavel P, Goudemand M (2001b). An 'accidental' acute psychosis with ecstasy use. J Psychoactive Drugs 33: 95-98.
56. Van Aerts LA, Mallaret M, Rigter H (2000). N-methyl-1- (1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. Addict Biol 5: 269-282.
57. Varma RS, Kabalka GW (1985). Synthesis of alkylamines via reduction of nitroalkenes using in situ prepared BH3 - THF. Synthetic Commun 15: 843-847.
58. Verrico CD, Miller GM, Madras BK (2005). MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 189: 489-503.